Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2022-11-23 1:01 pm Purchase |
2022-11-18 | 13G | TFF Pharmaceuticals, Inc. TFFP |
Laurence W. Lytton | 125,506 8.800% |
125,506 (New Position) |
Filing History |
| 2022-05-20 6:45 pm Purchase |
2022-05-11 | 13G | EMCORE Corporation EMKR |
Laurence W. Lytton | 204,390 5.400% |
139,112 (+213.10%) |
Filing History |
| 2022-05-18 4:47 pm Purchase |
2022-05-09 | 13G | Paratek Pharmaceuticals, Inc. PRTK |
Laurence W. Lytton | 3,210,552 5.900% |
3,210,552 (New Position) |
Filing History |
| 2022-03-30 12:48 pm Purchase |
2022-03-02 | 13G | Scientific Industries, Inc. SCND |
Laurence W. Lytton | 408,229 5.700% |
408,229 (New Position) |
Filing History |
| 2022-03-04 5:23 pm Purchase |
2022-02-22 | 13G | Catalyst Biosciences, Inc. CBIO |
Laurence W. Lytton | 472,615 5.900% |
442,952 (+1493.26%) |
Filing History |
| 2022-02-15 4:57 pm Purchase |
2021-12-31 | 13G | Apollo Endosurgery, Inc. APEN |
Laurence W. Lytton | 3,689,920 9.300% |
1,041,770 (+39.34%) |
Filing History |
| 2022-02-15 2:25 pm Sale |
2021-12-31 | 13G | DiaMedica Therapeutics Inc. DMAC |
Laurence W. Lytton | 1,071,970 4.100% |
-308,296 (-22.34%) |
Filing History |
| 2022-02-15 2:18 pm Sale |
2021-12-31 | 13G | VERTEX ENERGY INC VTNRQ |
Laurence W. Lytton | 3,649,067 5.700% |
-444,494 (-10.86%) |
Filing History |
| 2022-02-15 2:16 pm Purchase |
2021-12-31 | 13G | HTG Molecular Diagnostics, Inc. HTGM |
Laurence W. Lytton | 6,260,292 6.800% |
447,348 (+7.70%) |
Filing History |
| 2022-02-15 1:50 pm Sale |
2021-12-31 | 13G | Ra Medical Systems, Inc. RMED |
Laurence W. Lytton | 4,400 0.800% |
-419 (-8.70%) |
Filing History |
| 2022-02-15 1:49 pm Sale |
2021-12-31 | 13G | EMCORE Corporation EMKR |
Laurence W. Lytton | 65,279 1.800% |
-106,552 (-62.01%) |
Filing History |
| 2022-02-15 1:48 pm Purchase |
2021-12-31 | 13G | Viracta Therapeutics, Inc. VIRX |
Laurence W. Lytton | 255,876 0.700% |
255,876 (New Position) |
Filing History |
| 2022-02-15 1:09 pm Sale |
2021-12-31 | 13G | Cidara Therapeutics, Inc. CDTX |
Laurence W. Lytton | 85,416 2.500% |
-81,604 (-48.86%) |
Filing History |
| 2022-02-14 7:50 pm Sale |
2021-12-31 | 13G | Duos Technologies Group, Inc. DUOT |
Laurence W. Lytton | 214,700 5.900% |
-1,000 (-0.46%) |
Filing History |
| 2022-02-14 7:45 pm Purchase |
2021-12-31 | 13G | Giga-tronics Incorporated GIGA |
Laurence W. Lytton | 274,951 9.990% |
27,251 (+11.00%) |
Filing History |
| 2022-02-14 7:44 pm Sale |
2021-12-31 | 13G | Cellectar Biosciences, Inc. CLRB |
Laurence W. Lytton | 417,779 6.600% |
-56,621 (-11.94%) |
Filing History |
| 2021-12-30 12:27 pm Purchase |
2021-12-20 | 13G | LiqTech International, Inc. LIQT |
Laurence W. Lytton | 276,247 10.400% |
35,974 (+14.97%) |
Filing History |
| 2021-10-06 4:19 pm Purchase |
2021-09-26 | 13G | DiaMedica Therapeutics Inc. DMAC |
Laurence W. Lytton | 1,380,266 5.200% |
1,380,266 (New Position) |
Filing History |
| 2021-03-05 7:26 pm Purchase |
2021-02-25 | 13G | Cidara Therapeutics, Inc. CDTX |
Laurence W. Lytton | 167,020 7.000% |
30,666 (+22.49%) |
Filing History |
| 2021-03-05 4:55 pm Purchase |
2021-02-25 | 13G | Cidara Therapeutics, Inc. CDTX |
Laurence W. Lytton | 136,354 5.700% |
136,354 (New Position) |
Filing History |